By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Aid agency urges Johnson & Johnson to improve access to tuberculosis drug
Stocks

Aid agency urges Johnson & Johnson to improve access to tuberculosis drug

News Room
Last updated: 2023/09/30 at 6:32 PM
By News Room
Share
3 Min Read
SHARE

© Reuters. FILE PHOTO:The logo of Johnson & Johnson is seen on a Brussels’ office of the company in Diegem, Belgium September 21, 2023. REUTERS/Yves Herman/File Photo

GENEVA (Reuters) -Global health aid agency Unitaid has written to Johnson & Johnson (NYSE:)’s CEO, Joaquin Duato, urging “immediate action” to expand access to the company’s tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives.

While J&J has lowered the price of bedaquiline, which is used to treat drug-resistant tuberculosis (DR-TB), Unitaid said it was an “incomplete solution” and countries like South Africa, Belarus and Ukraine were not benefiting.

“Today Johnson & Johnson continues to enforce secondary patents in many of the countries with the highest burden of DR-TB, hindering generic manufacturer competition and impeding broader access to this critical medicine,” said the letter, signed by Unitaid’s executive director Philippe Duneton.

The agency is urging J&J to remove all secondary patents and ensure that lower prices are available to all countries with high TB cases.

J&J confirmed its intent not to enforce patents for bedaquiline in a statement on Friday, assuring current and future manufacturers that it will not allege them of infringing the drug’s patents, provided the “generic versions of SIRTURO produced or supplied by generic manufacturers are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries.”

A Unitaid spokesperson said it was unusual for the agency to publish its communications with the heads of pharmaceutical companies and it had done so because of the importance of the issue.

Earlier this month there was a high-level meeting on TB at the UN General Assembly, and advocates hope for more of a focus on the disease and better access to treatments.

TB, a bacterial disease that mostly affects the lungs, is preventable and treatable, but 10 million people catch it annually. Around 1.6 million people died from TB in 2021, almost entirely in low- and middle-income countries, according to the World Health Organization (WHO).

Multi-drug-resistant TB – a form of the disease that doesn’t respond to the standard drugs – is described by WHO as a “public health crisis”, with only one in three people who needed treatment in 2021 managing to access it.

Read the full article here

News Room September 30, 2023 September 30, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Is private equity becoming a money trap?

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Iran has increased enriched uranium by 50%, says UN watchdog

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Israel blocks Arab foreign ministers from meeting in West Bank

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

South Africa faces backlash over plan to change law for Musk’s Starlink

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Opec+ to boost oil output for third consecutive month

Stay informed with free updatesSimply sign up to the Oil myFT Digest…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?